A WORD FROM OUR CHIEF SCIENTIFIC OFFICER

Dear FAPI Community,

Hope everyone enjoyed a fun and relaxing summer. Our FAPI team has been very busy these last several months, and we can’t wait to share more of what’s on the horizon.

It was energizing seeing many of you this past June at the annual SNMMI meeting in New Orleans, both at the SOFIE booth (team pic above) and at our FAPI satellite symposium that drew great audience engagement and ended with the naming of our upcoming Phase 3 clinical trials. More details on that here.

We are working diligently to complete the end of our Phase 2 clinical trial efforts and gear up for launch of Phase 3 studies by year end. Our Global Outreach and Pharma Services programs also continue to grow.

I am attending EANM in Barcelona next month and hope to see some of you there. Please reach out if you’d like to schedule time to connect during the meeting.

Lastly, the educational section of the SOFIE website has been revamped making it even easier to navigate our curated collection of FAP/FAPI presentations and publications. 

We love receiving your feedback on our newsletter and other ways to continue building the FAPI community.  Wishing you all a fruitful fall season.

– Sherly Mosessian, Ph.D., Chief Scientific Officer

FAPI-74 CLINICAL DEVELOPMENT UPDATE

FAPI Pipeline August 2025

PUBLICATION HIGHLIGHTS

Each newsletter will feature recent FAPI publications.

90Y-FAPI-46 Theranostics Leads to Near-Complete Metabolic Response in 3 Patients with Solitary Fibrous Tumors

90Y-FAPI-46 Theranostics Leads to Near-Complete Metabolic Response in 3 Patients with Solitary Fibrous Tumors

J Nucl Med. 2025 Jul 24

[68Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trial

[68Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trial

Eur J Nucl Med Mol Imaging. 2025 Jul 16

Early image acquisition 68Ga-FAPI-46-PET/CT in prone position is promising in the workup of rectosigmoid and anal carcinoma

Early image acquisition 68Ga-FAPI-46-PET/CT in prone position is promising in the workup of rectosigmoid and anal carcinoma 

Sci Rep. 2025 May 14

FAPI OUTREACH PROGRAM

Join us in advancing the frontier of molecular imaging through the FAPI Outreach Program

SOFIE is continuing to accept applications for our FAPI Outreach Program. This program aims to raise awareness and foster collaboration in the field of molecular imaging, specifically focusing on Fibroblast Activation Protein Inhibitor (FAPI) studies. This program seeks to engage with healthcare professionals, researchers, and the broader community to share knowledge, advancements, and the potential impact of FAPI in diagnostic and therapeutic applications.

*GE Healthcare licensed products and regions are accepting new applications.

Copyright 2025 SOFIE CO. / ITHERANOSTICS INC. (21000 Atlantic Blvd. Suite 730  Dulles, VA  20166) all rights reserved.  The text or images in the newsletter may not be copied or distributed without prior permission of SOFIE. The SOFIE logo is a registered trademark of SOFIE CO. / ITHERANOSTICS INC., in the United States and/or other countries. All other trademarks referenced herein are the property of their respective owners. You have received this mail because you have subscribed for a newsletter at www.sofie.com or because you are an existing client or partner of SOFIE. If you no longer wish to receive these emails, click here to opt out.  This newsletter is meant to serve as an informational document as a service to our customers. The content or material provided is for informational purposes only and should and should not be construed as medical, legal, financial, investment, or other professional advice or opinion. SOFIE does not offer personalized medical advice or patient-specific treatment advice.